Skip to content

Link Between Abnormal Bleeding and Coagulation Disorders in Noonan Syndromes

Hemorrhagic Risk and Hemostasis Disorders in Noonan Syndrome and Related Conditions

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07259135
Acronym
PlatNoon
Enrollment
100
Registered
2025-12-02
Start date
2026-01-31
Completion date
2027-01-31
Last updated
2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Noonan Syndrome

Keywords

Noonan, Retrospective, Prediction, Hemorrhagic, Hemostasis, Bleeding, Surgery

Brief summary

Noonan syndrome is a relatively rare genetic disorder, affecting around 1 in every 1,000 to 2,500 children born. Patients often have a tendency to bleed more easily, particularly from the skin or mucocutaneous tissue (such as mouth or nose). Around half of all the patients are affected by bleedings. The causes of bleeding are variable : some are linked to platelet disorders, others to more complex coagulation problems. However, it is difficult to predict exactly which patients are at risk of severe bleeding, for example during surgery. This is why there are as yet no clear recommendations for preventing this risk before medical intervention. However, it is recommended that patients with Noonan syndrome consult a specialist to assess this risk. Unfortunately, the tests carried out are often unreliable in predicting this significant risk of bleeding. In this study, data from a large group of patients with Noonan syndrome, followed-up in different centers in France, will be studied. During a medical meeting as part of their regular follow-up, a medical doctor assessed their tendency to bleed using a standardized questionnaire (standardized ISTH-BAT score). These results will be compared with the biological tests also performed during their medical follow-up. The aim is to better understand whether these tests are useful in predicting the risk of bleeding. Ultimately, this could help practicians to better anticipate surgical or medical interventions in these patients, and limit bleeding-related risk.

Detailed description

Noonan syndrome (NS) is an autosomal dominant genetic disorder, with an estimated prevalence of 1 in 1,000 to 2,500 births/year. Patients with NS have a cutaneous-mucosal hemorrhagic diathesis, with a prevalence estimated at 46% in a large meta-analysis. The most frequently reported abnormalities are those of primary hemostasis (thrombocytopenia, thrombopathy and Willebrand's disease), as well as those of coagulation, but the correlation between symptomatology and hemostatic disorders is unclear. As a result, there are no specific recommendations in terms of intraoperative hemorrhagic risk prevention, due to a lack of knowledge of the real hemorrhagic risk in these patients, who are particularly exposed to invasive procedures. The PNDS recommends that patients be referred to a haemostasis specialist for assessment of bleeding risk, which entails the performance of investigations that are often not very predictive of bleeding risk. Interpretation of these results with regard to bleeding risk therefore remains unsolved. It is against this backdrop that the aim of this study is to retrospectively collect the bleeding diathesis of a national cohort of patients with SN, using a standardized ISTH-BAT score, performed in the context of a specialized hemostasis consultation by a physician from one of the centers involved in this study. The hemorrhagic diathesis will be compared with the results of the hemostasis exploration performed as part of their follow-up (routine care). This study will make it possible to assess the value of a hemostasis study in predicting the risk of bleeding in these patients.

Interventions

OTHERReuse of routine clinical and biological data

Reuse of routine clinical and biological data

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All patients with SN, regardless of age * Patient/parental guardians informed of the study * Patient/legal representative not opposed to the use of their/the child's data * Person affiliated or benefiting from a social security scheme

Exclusion criteria

\- Adults protected by law (guardianship, curatorship or safeguard of justice)

Design outcomes

Primary

MeasureTime frameDescription
ISTH-BAT haemorrhagic scoreAt first clinical visit in the referent center (retrieved retrospectively at inclusion visit)The ISTH-BAT standardized questionnaire uses 14 items to assess the severity of cutaneous-mucosal, cerebral, articular and per- or post-operative haemorrhagic symptoms
Willebrand factorAt first clinical visit in the referent center (retrieved retrospectively at inclusion visit)The Willebrand factor will be obtained from biological tests (in percentage of controls mean value)
Platelet functionAt first clinical visit in the referent center (retrieved retrospectively at inclusion visit)Platelet function will be obtained from biological tests (in percentage of controls mean value)

Countries

France

Contacts

Primary ContactMathieu FIORE
mathieu.fiore@chu-bordeaux.fr05 57 65 64 78
Backup ContactValérie GOIN MONSINJON
valerie.goin@chu-bordeaux.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026